UT-COHEREX-MEDICAL
Coherex Medical, Inc. announced it has received CE Mark approval for its Coherex WaveCrest™ LAA Occlusion System.
Atrial fibrillation (AF) is the most common cardiac arrhythmia in today’s aging population, affecting nearly 6 million individuals in the US alone. AF causes the upper chambers of the heart to beat irregularly, slowing the flow of blood through these chambers and increasing the risk for stroke as this slower blood flow can cause clots to form.
The Left Atrial Appendage (LAA) is a pouch like cul-de-sac attached to the left atrium, which is recognized as the source of blood clots in approximately 90% of patients who have AF. Historically, patients who are at increased risk for stroke due to other medical conditions have had to take anticoagulants (blood thinners) to help prevent these clots from forming. These anticoagulant medications have many side effects, and in many patients may not be tolerated over the long term. The WaveCrest LAA Occluder is an implantable device that seals off the LAA opening so clots cannot escape into the blood stream and cause a stroke.
According to Coherex President and CEO Alex Martin, “The Coherex WaveCrest LAA Occluder provides substantial benefits for patients with AF who are at high risk for stroke. The WaveCrest is a one-time treatment option for patients who would otherwise be on a lifetime regimen of anticoagulation therapy or who are contraindicated to anticoagulants altogether and would therefore be unprotected from the risk of cardio embolism.”
Coherex recently presented results from the WAVECREST I clinical trial at the Paris Course on Revascularization (PCR). The company has been conducting a worldwide clinical trial to study the safety and efficacy of the WaveCrest LAA Occlusion System. Added Mr. Martin, “We are extremely proud of the clinical results to date and anticipate quick adoption of the device in the commercial setting.”
The company also announced today that it has entered into an exclusive distribution agreement with Biosense Webster Inc. for the Coherex WaveCrest LAA Occlusion System.
Under terms of the agreement, Coherex will provide exclusive worldwide distribution rights, excluding the US, to Biosense Webster for the CE-marked Coherex WaveCrest Device. Biosense Webster, along with its affiliated company, Cordis Corporation, will promote, train, sell and support the WaveCrest device. Coherex Medical will manufacture the Coherex WaveCrest LAA Occlusion System at its facility in Salt Lake City.
“I am pleased to report that Coherex has accomplished three major objectives,” said Mr. Martin. “First, we have completed our WAVECREST I clinical trial. Second, we have successfully attained CE Mark clearance for the WaveCrest LAA Occlusion System. And third, we are partnering with Biosense Webster in a distribution agreement to market and sell our WaveCrest implant in many countries throughout the world. Biosense Webster is a market leader in atrial fibrillation with significant global reach and expertise. I am very excited that Coherex is entering into this distribution agreement with Biosense Webster.”
The company expects to have a controlled product launch in Europe. Coherex plans to conduct additional clinical trials designed to lead to final approval in the USA and Japan.
About Coherex Medical
Formed in 2003, Coherex Medical addresses structural heart disease and conditions through the development of innovative medical devices. Please visit www.coherex.com or call 801-433-9900.
Contact:
Coherex Medical
Mike Simmons, 801-433-9900
www.coherex.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Delivers Record First Quarter Net Sales of 1.129 Billion USD, Including Strong Performance From Two Launches With Blockbuster Potential, and Confirms Full-Year Guidance24.4.2025 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2025. Net sales: Achieved 1,129 million USD in net sales, up 8.3% year-on-year on a constant currency basis, primarily driven by volume, complemented by favorable mix Results ahead of expectations: Net sales benefited from focused execution, favorable phasing in Injectable Aesthetics, and stronger than expected ramp-up of Nemluvio Broad-based growth: Strong performance momentum across product categories and across geographies, with constant currency year-on-year growth of 9.9% for Injectable Aesthetics, 7.8% for Dermatological Skincare, and 4.9% for Therapeutic Dermatology, which includes net sales of 39 million USD for Nemluvio® (nemolizumab) Innovation, science and education leadership: Further advanced its category leadership in dermatology: with the launch of Nemluvio and Relfydess™ (RelabotulinumtoxinA),
Engelhart and e.optimum Strengthen Their Partnership With a Further Onshore Wind PPA, Supporting Germany’s Energy Transition24.4.2025 07:00:00 CEST | Press release
The Global Commodities and Renewable Energy Trader, Engelhart, is delighted to announce the signing of a further power purchase agreement (PPA) with e.optimum, one of Germany’s largest independent energy suppliers. Following the first PPA signed in January 2025, this new agreement secures renewable electricity from additional onshore wind turbines with a total capacity of approximately 167 MWfromJuly to December 2025. This is enough green power to supply around 31,000 households. This second PPA marks a significant expansion of the partnership between the two companies. It represents a 195% increase in contracted capacity, bringing the total from 86 MW to 253 MW of onshore wind power. Furthermore, the agreement contributes directly to Germany’s transition to a net zero-carbon economy by 2045. Matthias Seel, Senior Originator Corporate Customers Europe at Engelhart, commented: "The second PPA with e.optimum is another milestone in our joint partnership. Especially in uncertain economic
Textron Aviation Raises the Bar for Workforce Development With State-of-the-Art Career & Learning Center23.4.2025 22:00:00 CEST | Press release
Textron Aviation Inc. a Textron Inc. (NYSE: TXT) company, today announced its new Career & Learning Center is complete and fully operational serving prospective, current and future Textron Aviation employees. Strategically located on the company’s East Wichita Campus, this state-of-the-art facility expands the training footprint to more than 75,000 square feet and provides a world-class employee experience during the application, hiring, onboarding and training processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423874476/en/ Textron Aviation Career and Learning Center | Textron Aviation “The Textron Aviation Career & Learning Center is an important investment in building the next generation of aviation manufacturing, support and professional talent,” said Ron Draper, president and CEO. “Recruiting, hiring and training a world-class workforce is vital to our ability to provide the best aviation experience for our cu
TSMC Unveils Next-Generation A14 Process at North America Technology Symposium23.4.2025 20:40:00 CEST | Press release
Showcasing TSMC’s latest offerings for high performance computing, smartphone, automotive, and IoT applications TSMC (TWSE: 2330, NYSE: TSM) today unveiled its next cutting-edge logic process technology, A14, at the Company’s North America Technology Symposium. Representing a significant advancement from TSMC’s industry-leading N2 process, A14 is designed to drive AI transformation forward by delivering faster computing and greater power efficiency. It is also expected to enhance smartphones by improving their on-board AI capabilities, making them even smarter. Planned to enter production in 2028, the current A14 development is progressing smoothly with yield performance ahead of schedule. Compared with the N2 process, which is about to enter volume production later this year, A14 will offer up to 15% speed improvement at the same power, or up to 30% power reduction at the same speed, along with more than 20% increase in logic density. Leveraging the Company’s experience in design-tech
Veracode Delivers End-to-End Risk Coverage with New Tools: AI-Powered Dynamic Analysis Security Testing with External Attack Surface Management23.4.2025 17:42:00 CEST | Press release
Seamless Integration and Speed: Latest Innovations Empower Faster, Smarter, and Safer Software Security Veracode, a global leader in application risk management, today announced new capabilities to help organizations address emerging threats, giving security professionals better visibility and control in one place. The launch includes new AI-powered functionality in the Dynamic Application Security Testing (DAST)product and an External Attack Surface Management (EASM) capability. Together, they enable security teams to discover their entire attack surface and prioritize the most critical risk to streamline and simplify security scanning. “Security teams need to see and secure everything; not only what is inside their perimeter,” said Derek Maki, Head of Product at Veracode. “With our latest DAST capabilities and Application Risk Management platform enhancements, we’re helping organizations shift from vulnerability scanning to holistic risk management, to better identify risk residing i
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum